Phase 1b/II study of cancer sternness inhibitor napabucasin (BBI-608) in combination with FOLFIRI plus /- bevacizumab (bev) in metastatic colorectal cancer (mCRC) patients (pts).

被引：28
|
作者：
Bendel, Johanna C.
Hubbard, Joleen Marie
O'Neil, Bert H.
Jonker, Derek J.
Starodub, Alexander
Peyton, James D.
Pitot, Henry C.
Halfdanarson, Thorvardur Ragnar
Nadeau, Benjamin Rolland
Zubkus, John D.
Adesunloye, Bamidele
Edenfield, William Jeffery
Li, Youzhi
Li, Wei
Grothey, Axel
Borodyansky, Laura
Li, Chiang
机构：
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2017年 / 35卷
关键词：
D O I：
10.1200/JCO.2017.35.15_suppl.3529
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
3529
引用
收藏
页数：5
相关论文
共 50 条
  • [1] Cancer stemness inhibition and chemosensitization: Phase 1b/II study of cancer stemness inhibitor napabucasin (BBI-608) with FOLFIRI plus /- bevacizumab (Bev) administered to colorectal cancer (CRC) patients (pts).
    Bendell, Johanna C.
    O'Neil, Bert H.
    Starodub, Alexander
    Jonker, Derek J.
    Halfdanarson, Thorvardur Ragnar
    Edenfield, William Jeffery
    El-Rayes, Bassel F.
    Hubbard, Joleen Marie
    Pitot, Henry C.
    Hobday, Timothy J.
    Li, Youzhi
    Gao, Yuan
    Grothey, Axel
    Borodyansky, Laura
    Li, Chiang
    JOURNAL OF CLINICAL ONCOLOGY, 2017, 35 (04)
  • [2] Phase 1b/II study of cancer stemness inhibitor napabucasin in combination with FOLFIRI plus /-evacizumab (bev) in metastatic colorectal cancer (mCRC) patients (pts)
    Bendell, J.
    Hubbard, J.
    O'Neil, B. H.
    Jonker, D.
    Starodub, A.
    Peyton, J.
    Pitot, H.
    Halfdanarson, T.
    Nadeau, B.
    Zubkus, J.
    Adesunloye, B.
    Edenfield, J.
    Li, Y. Z.
    Li, W.
    Grothey, A.
    Borodyansky, L.
    Li, C. J.
    ANNALS OF ONCOLOGY, 2017, 28
  • [3] Phase 1b extension study of cancer stemness inhibitor BB608 (napabucasin) administered in combination with FOLFIRI plus /-bevacizumab (Bev) in patients (pts) with advanced colorectal cancer (CRC).
    O'Neil, Bert H.
    Hubbard, Joleen Marie
    Starodub, Alexander
    Jonker, Derek J.
    Edenfield, William Jeffery
    El-Rayes, Bassel F.
    Halfdanarson, Thorvardur Ragnar
    Ramanathan, Ramesh K.
    Pitot, Henry C.
    Britten, Carolyn D.
    Adesunloye, Bamidele
    Grothey, Axel
    Borodyansky, Laura
    Li, Chiang
    JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (15)
  • [4] Phase Ib study of cancer stem cell (CSC) pathway inhibitor BBI-608 administered in combination with FOLFIRI with and without bevacizumab (Bev) in patients (pts) with advanced colorectal cancer (CRC).
    Hubbard, Joleen Marie
    O'Neil, Bert H.
    Jonker, Derek J.
    Halfdanarson, Thorvardur Ragnar
    Starodub, Alexander
    Grothey, Axel
    Borodyansky, Laura
    Li, Chiang
    JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (04)
  • [5] A phase Ib/II study of cancer sternness inhibitor napabucasin (BBI-608) in combination with gemcitabine (gem) and nab-paclitaxel (nabPTX) in metastatic pancreatic adenocarcinoma (mPDAC) patients (pts).
    Bekaii-Saab, Tanios S.
    Starodub, Alexander
    El-Rayes, Bassel F.
    O'Neil, Bert H.
    Shanda, Safi
    Ciombor, Kristen Keon
    Noonan, Anne M.
    Hanna, Wahid Tewfik
    Sehdev, Amikar
    Shaib, Walid Labib
    Mikhail, Sameh
    Neki, Anterpreet S.
    Oh, Cindy
    Li, Youzhi
    Li, Wei
    Borodyansky, Laura
    Li, Chiang
    JOURNAL OF CLINICAL ONCOLOGY, 2017, 35
  • [6] BBI608-224: A phase Ib/II study of cancer stemness inhibitor napabucasin (BBI-608) administered with panitumumab in KRAS wild-type patients with metastatic colorectal cancer
    Larson, Tim
    Ortuzar, Waldo Feliu
    Bekaii-Saab, Tanios S.
    Becerra, Carlos
    Ciombor, Kristen Keon
    Hubbard, Joleen Marie
    Edenfield, William Jeffery
    Shao, Spencer H.
    Grothey, Axel
    Borodyansky, Laura
    Xu, Bo
    Li, Wei
    Li, Youzhi
    Li, Chiang
    Khan, Waheed
    JOURNAL OF CLINICAL ONCOLOGY, 2017, 35 (04)
  • [7] Phase I study of napabucasin in combination with FOLFIRI plus bevacizumab in Japanese patients with metastatic colorectal cancer
    Taniguchi, Hiroya
    Masuishi, Toshiki
    Kawazoe, Akihito
    Muro, Kei
    Kadowaki, Shigenori
    Bando, Hideaki
    Iino, Shuichi
    Kageyama, Rie
    Yoshino, Takayuki
    INTERNATIONAL JOURNAL OF CLINICAL ONCOLOGY, 2021, 26 (11) : 2017 - 2024
  • [8] A phase Ib study of BBI608 in combination with FOLFIRI with and without bevacizumab in patients (pts) with advanced colorectal cancer (CRC)
    Hubbard, Joleen Marie
    Jonker, Derek J.
    O'Neil, Bert H.
    Halfdanarson, Thorvardur Ragnar
    Grothey, Axel
    Li, Youzhi
    Borodyansky, Laura
    Li, Chiang
    JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (15)
  • [9] Phase I study of napabucasin in combination with FOLFIRI + bevacizumab in Japanese patients with metastatic colorectal cancer
    Hiroya Taniguchi
    Toshiki Masuishi
    Akihito Kawazoe
    Kei Muro
    Shigenori Kadowaki
    Hideaki Bando
    Shuichi Iino
    Rie Kageyama
    Takayuki Yoshino
    International Journal of Clinical Oncology, 2021, 26 : 2017 - 2024
  • [10] Axitinib or bevacizumab (bev) plus FOLFOX or FOLFIRI as second-line therapy in patients (pts) with metastatic colorectal cancer (mCRC)
    Bendell, J. C.
    Tournigand, C.
    Bednarczyk, M.
    Swieboda-Sadlej, A.
    Chung, I.
    Barone, C.
    Tarazi, J. C.
    Rosbrook, B.
    Ricart, A. D.
    Sobrero, A. F.
    JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (04)
12345